Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis
- 11 July 2008
- journal article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 27 (10), 1307-1311
- https://doi.org/10.1007/s10067-008-0960-7
Abstract
Increasing evidence supports the concept of macrophage migration inhibitory factor (MIF) as a central proinflammatory cytokine in autoimmune diseases. To further evaluate its role in systemic sclerosis (SSc), serum levels of MIF were determined by enzyme-linked immunoassay, and correlations to clinical manifestations were analyzed in 43 patients. MIF levels were significantly increased in patients (median, 18.8; range, n = 43, 8.0, P < 0.0005). MIF values were higher in diffuse than in limited cutaneous SSc (P < 0.005). Patients with pulmonary hypertension and recurrent digital ulcers showed higher MIF levels than patients without these manifestations (P < 0.005). This association was also observed in limited cutaneous SSc. Sequential studies revealed decreased MIF levels after initiation of immunosuppressive therapy. MIF levels were not significantly different in patients with and without macrovascular disease of the peripheral arteries. The results suggest that MIF might contribute to inflammation and vasculopathy in SSc.This publication has 25 references indexed in Scilit:
- The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytesInternational Journal of Molecular Medicine, 2006
- Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.2006
- Scleroderma: from cell and molecular mechanisms to disease modelsTrends in Immunology, 2005
- Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis.2000
- Macrovascular disease and systemic sclerosisAnnals Of The Rheumatic Diseases, 2000
- Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosisRheumatology, 1997
- An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.Proceedings of the National Academy of Sciences of the United States of America, 1996
- MIF as a glucocorticoid-induced modulator of cytokine productionNature, 1995
- The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.The Journal of Experimental Medicine, 1994
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980